Kappa Bioscience renames its subsidiary, Synthetica, to Kappa Solutions

The company introduced Kappa Solutions to strengthen its value proposition and harmonize its brand.

The Kappa Bioscience Group (Oslo, Norway) renamed its subsidiary Synthetica—for its custom organic synthesis and analytical services for the pharmaceutical and dietary supplements industries—to Kappa Solutions.

“In 2008, Synthetica researchers were the first to develop and patent a large-scale method to synthesize all-trans vitamin K2 MK 7 in its purest form,” explained Egil Greve, CEO of the Kappa Bioscience Group, in a press release.

“Marketed under the brand K2Vital, our synthetic vitamin K2 MK-7 has become the reference standard for analytical labs worldwide, used for both quantity measurement and cis/trans purity assessment. Kappa became the certified vendor to the United States Pharmacopeia (USP),” added Inger Reidun Aukrust, PhD, vice president of R&D and chemistry.

Dominik Mattern, VP of marketing, explained in a press release that the company introduced Kappa Solutions to strengthen its value proposition and harmonize its brand. “The new name emphasizes the solution-oriented, customer-centric approach of Kappa Solutions and its extensive portfolio for custom organic synthesis, process development, analytical services, and drug (API) development, including cGMP manufacturing, for the pharmaceutical and dietary supplements industries,” he said. “Kappa Solutions aims to be your preferred partner for drug development and analytical services.”